Aleniglipron
ACCESS
Gasherbrum Bio, Inc · Phase 2 · Completed · Enrollment 230
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Cohort 1 | n/r | n/r | n/r | n/r |
| Cohort 2 | n/r | n/r | n/r | n/r |
| Cohort 3 | n/r | n/r | n/r | n/r |
| Cohort 1 OLE | n/r | n/r | n/r | n/r |
| Cohort 2 OLE | n/r | n/r | n/r | n/r |
| Cohort 3 OLE | n/r | n/r | n/r | n/r |
| Cohort 4 OLE | n/r | n/r | n/r | n/r |
Not shown
- Cohort 1: endpoint not reported
- Cohort 2: endpoint not reported
- Cohort 3: endpoint not reported
- Cohort 1 OLE: endpoint not reported
- Cohort 2 OLE: endpoint not reported
- Cohort 3 OLE: endpoint not reported
- Cohort 4 OLE: endpoint not reported